Penumbra Inc (NYSE:PEN) CEO Adam Elsesser sold 8,000 shares of Penumbra stock in a transaction that occurred on Monday, August 12th. The stock was sold at an average price of $149.24, for a total value of $1,193,920.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Adam Elsesser also recently made the following trade(s):

  • On Thursday, July 11th, Adam Elsesser sold 8,000 shares of Penumbra stock. The stock was sold at an average price of $171.84, for a total value of $1,374,720.00.
  • On Tuesday, June 11th, Adam Elsesser sold 8,000 shares of Penumbra stock. The stock was sold at an average price of $165.08, for a total value of $1,320,640.00.

Shares of PEN stock traded down $3.47 during trading hours on Wednesday, reaching $148.50. The company’s stock had a trading volume of 292,400 shares, compared to its average volume of 406,800. The company has a market capitalization of $5.18 billion, a PE ratio of 291.18, a P/E/G ratio of 8.45 and a beta of 0.65. Penumbra Inc has a one year low of $110.84 and a one year high of $185.70. The business’s fifty day moving average is $165.79. The company has a debt-to-equity ratio of 0.10, a current ratio of 6.23 and a quick ratio of 4.33.

Penumbra (NYSE:PEN) last issued its quarterly earnings data on Tuesday, August 6th. The company reported $0.27 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.21 by $0.06. The firm had revenue of $134.20 million for the quarter, compared to analyst estimates of $130.67 million. Penumbra had a return on equity of 6.80% and a net margin of 3.03%. The business’s quarterly revenue was up 22.4% compared to the same quarter last year. During the same period last year, the company earned $0.15 EPS. Analysts expect that Penumbra Inc will post 0.9 earnings per share for the current year.

A number of brokerages have commented on PEN. Royal Bank of Canada set a $174.00 price target on Penumbra and gave the stock a “buy” rating in a research note on Wednesday, August 7th. HC Wainwright reaffirmed a “buy” rating on shares of Penumbra in a research note on Wednesday, April 17th. Wells Fargo & Co lifted their price target on Penumbra from $180.00 to $185.00 and gave the stock an “outperform” rating in a research note on Thursday, August 1st. Zacks Investment Research cut Penumbra from a “buy” rating to a “hold” rating in a research note on Thursday, August 1st. Finally, Bank of America lifted their price target on Penumbra from $150.00 to $180.00 and gave the stock a “buy” rating in a research note on Thursday, June 13th. Three analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $167.14.

Several hedge funds have recently modified their holdings of the company. Putnam Investments LLC raised its stake in shares of Penumbra by 0.6% in the second quarter. Putnam Investments LLC now owns 566,449 shares of the company’s stock worth $90,632,000 after purchasing an additional 3,301 shares during the last quarter. Ellington Management Group LLC purchased a new stake in Penumbra during the second quarter valued at $208,000. Rock Springs Capital Management LP increased its position in Penumbra by 6.2% during the second quarter. Rock Springs Capital Management LP now owns 239,000 shares of the company’s stock valued at $38,240,000 after acquiring an additional 14,000 shares during the last quarter. A.R.T. Advisors LLC purchased a new stake in Penumbra during the second quarter valued at $378,000. Finally, Holocene Advisors LP purchased a new stake in Penumbra during the second quarter valued at $372,000. Hedge funds and other institutional investors own 90.29% of the company’s stock.

Penumbra Company Profile

Penumbra, Inc designs, develops, manufactures, and markets medical devices in the United States, Europe, Canada, Australia, Japan, and internationally. The company offers neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, DDC, and PX SLIM brands; aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the ACE and the 3D Revascularization Device brands.

See Also: Reverse Stock Split

Insider Buying and Selling by Quarter for Penumbra (NYSE:PEN)

Receive News & Ratings for Penumbra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Penumbra and related companies with MarketBeat.com's FREE daily email newsletter.